OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
17 Octobre 2024 - 6:00PM
UK Regulatory
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific
Technology for the Design of Cytokine Drugs with Improved
Therapeutic Index
NANTES, France, October 17, 6:00pm CET -
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo:
OSE), today announced it will be presenting its novel
OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral
presentations selected for international conferences:
- The Festival of
Biologics in Basel, Switzerland (October 17, 2024)
- The
16th Annual Protein & Antibody Engineering Summit
(PEGS) Europe Summit in Barcelona, Spain (November 7, 2024)
- The Antibody
Therapeutics Xchange in Brussels (November 18, 2024)
OSE-CYTOMASK is an innovative proprietary
non-cleavable linker technology to create a new class of regulated
and targeted cytokine therapeutics that deliver highly active
medicines with improved therapeutic index. The presentations
highlight the rational design of the technology through two first
preclinical programs based on anti-PD1 masked cytokine (IL-2,
IL-15) in oncology with conditional Cis-Demasking and
Cis-Potentiation of tumor-specific T cells expressing PD1 or other
immune targets.
Aurore Morello, Head of Research, OSE
Immunotherapeutics, said: “We are very happy to
present our novel OSE-CYTOMASK technology at upcoming leading
scientific conferences. Our novel linker technology allows
conditional Cis-Demasking of cytokine, through PD1-targeting on
tumor-specific T cells, without relying on protease-cleavable
technology or mutagenesis of cytokine to abrogate off-tumor
activity associated with significant toxicity of the majority of
cytokines from this class of drugs. The high preclinical efficacy
observed in monotherapy and good tolerance profile of the first two
drug candidates selected open the way to a potential novel
first-in-class treatment for patients in high need of new
therapeutic options in oncology.”
Nicolas Poirier, Chief Executive
Officer, OSE Immunotherapeutics, adds: “We are proud
of the achievements from our research team on the advancement of
these programs. This highly innovative technology promises to
unleash the full potential of cytokines in oncology by dramatically
increasing the therapeutic index of this class of drugs. We are
also interested in potential applications of this innovative
technology in autoimmune and inflammatory diseases.”
Immunostimulatory cytokines are a highly potent
class of drug to reactivate the immune system against tumors. Their
narrow therapeutic index is associated with significant peripheral
toxicity and limited drug exposure in the tumor microenvironment
(TME), limiting their clinical development.
Current conditional cytokine masking approaches
relying on theoretical demasking activity in the TME with cleavable
linker technologies by enzymes produce more selectively by the
tumors have already demonstrated their limitation due to the
heterogenous protease expression in tumors (variable on-tumor
activation across patients) and non-specific protease expression in
non-tumor sites (off-tumor cytokine activity). We have engineered
an innovative non-cleavable recombinant linker technology allowing
specific conditional delivery of cytokine activity only where
needed based on an original targeted Cis-Demasking mechanism
independent of proteases expression.
OSE-CYTOMASK technology has been used first to
implement our proprietary anti-PD1 BiCKI® platform in order to
improve the therapeutic index of highly active cytokines (eg.,
IL-2, IL-15…). The Company presented two first preclinical programs
with anti-PD1/masked IL-2 and anti PD1/masked IL-15 with robust
preclinical efficacy demonstrated in monotherapy leading to a high
rate of anti-tumor response and eradication in different models
(eg. orthotopic pancreatic tumor, melanoma or colon cancer) in the
absence of peripheral toxicity in dose-response illustrating
significantly improved therapeutic index of both IL-2 or IL-15
using the OSE-CYTOMASK technology.
Presentations: details
Festival of Biologics (October 17), Basel
Presenter: Aurore Morello, PhD., Head of Research, OSE
Immunotherapeutics
“OSE- Cytomask Technology: Cis-Demasking Cytokine
Technology for targeted Delivery”
October 17, 11:30
Protein & Antibody Engineering Summit (PEGS) Europe
Summit (November 7),
Barcelona
Presenter: Nicolas Poirier, PhD, Chief Executive Officer, OSE
Immunotherapeutics
“OSE-CYTOMASK: Cis-Demasking Cytokine Technology with
Non-Cleavable Linker”
November 7, 16:40
Antibody Therapeutics Xchange (November
18), Brussels
Presenter: Aurore Morello, PhD., Head of Research, OSE
Immunotherapeutics
“Addressing challenges faced for optimal bi-specific
and Immunocytokines engineering”
November 18, 09:05 - 10:05
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotech company
dedicated to developing first-in-class assets in immuno-oncology
(IO) and immuno-inflammation (I&I).
The Company’s current well-balanced first-in-class clinical
pipeline includes:
-
Tedopi® (immunotherapy
activating tumor specific T-cells, off-the-shelf,
neoepitope-based): most advanced therapeutic cancer vaccine in
development; positive results from a randomized Phase 3 trial
(Atalante 1) in Non-Small Cell Lung Cancer patients in third-line
secondary resistance after checkpoint inhibitor failure. Ongoing
randomized registration Phase 3 study (Artemia) in second-line
NSCLC in HLA-A2+ patients with secondary resistance. Other Phase 2
trials, sponsored by clinical oncology groups, of
Tedopi® in combination are ongoing in solid tumors.
- OSE-127 -
Lusvertikimab (humanized monoclonal antibody antagonist of
IL-7 receptor); Positive Phase 2 (CoTikiS) study in Ulcerative
Colitis; ongoing preclinical research in leukemia.
- OSE-279
(anti-PD1): first positive results in the ongoing Phase 1/2 in
solid tumors.
- FR-104/VEL-101
(anti-CD28 monoclonal antibody): developed in partnership with
Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2
in renal transplant (sponsor Nantes University Hospital);
successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals,
Inc.).
- Anti-SIRPα monoclonal
antibody developed in partnership with Boehringer
Ingelheim in advanced solid tumors and
cardiovascular-renal-metabolic diseases (CRM); positive Phase 1
dose escalation results in monotherapy and in combination; Phase 2
in CRM diseases planned to be initiated end of 2024.
- ABBV-230 (ChemR23
agonist mAb) developed in partnership with AbbVie in chronic
inflammation.
OSE Immunotherapeutics expects to generate
further significant value from its three proprietary drug discovery
platforms, which are central to its ambitious goal to deliver
next-generation first-in-class immunotherapies:
- Pro-resolutive mAb
platform focused on targeting and advancing inflammation
resolution and optimizing the therapeutic potential of targeting
Neutrophils and Macrophages in I&I. ABBV-230
(licensed to AbbVie) is the first candidate generated by the
platform, additional discovery programs ongoing on new
pro-resolutive GPCRs.
- Myeloid Checkpoint
platform focused on optimizing the therapeutic potential
of myeloid cells in IO by targeting immune regulatory receptors
expressed by Macrophages and Dendritic cells. BI
765063 and BI 770371 (licensed to
Boehringer Ingelheim) are the most advanced candidates generated by
the platform. Ongoing additional discovery programs, in particular
with positive preclinical results obtained in monotherapy with new
anti-CLEC-1 mAbs.
-
BiCKI®
Platform is a bifunctional fusion protein platform
built on the key backbone component of anti-PD1 combined with a new
immunotherapy target to increase anti-tumor efficacy by
“cis-potentiating” tumor-specific T cells. A first program has been
acquired by Boehringer Ingelheim. OSE-CYTOMASK is
an innovative technology to create cytokine therapeutics with
improved therapeutic index.
- mRNA Therapeutic
platform allows local delivery into the inflammatory site
of innovative immunotherapies encoded by RNA to locally controls
and/or suppress immune responses and inflammation.
Additional information about OSE
Immunotherapeutics assets is available on the Company’s website:
www.ose-immuno.com. Follow us on X and LinkedIn
Contacts
Sylvie Détry
sylvie.detry@ose-immuno.com
Nicolas Poirier
Chief Executive Officer nicolas.poirier@ose-immuno.com
|
French
Media: FP2COM
Florence Portejoie
fportejoie@fp2com.fr
+33 6 07 768 283
U.S. Media Contact
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
|
|
Forward-looking statements
This press release contains express or implied information and
statements that might be deemed forward-looking information and
statements in respect of OSE Immunotherapeutics. They do not
constitute historical facts. These information and statements
include financial projections that are based upon certain
assumptions and assessments made by OSE Immunotherapeutics’
management in light of its experience and its perception of
historical trends, current economic and industry conditions,
expected future developments and other factors they believe to be
appropriate.
These forward-looking statements include statements typically using
conditional and containing verbs such as “expect”, “anticipate”,
“believe”, “target”, “plan”, or “estimate”, their declensions and
conjugations and words of similar import. Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE
Immunotherapeutics’ shareholders and other investors are cautioned
that the completion of such expectations is by nature subject to
various risks, known or not, and uncertainties which are difficult
to predict and generally beyond the control of OSE
Immunotherapeutics. These risks could cause actual results and
developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by
OSE Immunotherapeutics with the AMF. Such forward-looking
statements are not guarantees of future performance. This press
release includes only summary information and should be read with
the OSE Immunotherapeutics Universal Registration Document filed
with the AMF on April 30, 2024, including the annual financial
report for the fiscal year 2023, available on the OSE
Immunotherapeutics’ website. Other than as required by applicable
law, OSE Immunotherapeutics issues this press release at the date
hereof and does not undertake any obligation to update or revise
the forward-looking information or statements.
1 Cis-Demasking: Bispecific
antibodies (*) have the capability to
target cells either in a Cis- targeting (on the same cell) or in a
Trans-binding orientation (between two different cells).
Cis-Demasking bispecific technology targets two antigens expressed
on the same cell, with one masked modality (eg. Cytokine) and
enabling conditional activity of the cytokine on the desired immune
cell types upon antibody binding.
(*) Segués A.
et al. International Review of Cell and Molecular Biology
2022.
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
OSE Immunotherapeutics (EU:OSE)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024